
CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet
CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026 — here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.